Llado 2006.

Methods	Randomised clinical trial
Participants	Country: Spain Period of recruitment: 2001‐2004 Number randomised: 200 Post‐randomisation dropouts: 2 (1.0%) Revised sample size: 198 Reasons for post‐randomisation dropouts: protocol violations Average age (years): 54 Females: 43 (21.7%) Primary transplantation: 198 (100.0%) Reason for transplantation Alcohol‐related cirrhosis: 55 (27.8%) Viral‐related cirrhosis: 60 (30.3%) Autoimmune disease‐related cirrhosis: 0 (0.0%) HCC: 63 (31.8%) Others: 20 (10.1%) Maintenance immunosuppression used during induction immunosuppression: cyclosporin A plus mycophenolate mofetil Altered immunosuppression after withdrawal: no Other exclusion criteria: transplant for fulminant liver disease multiorgan transplant HIV infection
Interventions	Group 1: basiliximab (n = 96) Further details: basiliximab as two 20 mg doses: the first dose was administered within 6 hours of reperfusion (day 0), and the second dose on day 4 after transplantation Group 2: basiliximab + glucocorticosteroids (n = 102) Further details: basiliximab as two 20 mg doses: the first dose was administered within 6 hours of reperfusion (day 0), and the second dose on day 4 after transplantation + methylprednisolone (500 mg) as a single intravenous bolus before reperfusion; and afterwards, 0.5 mg/kg/day methylprednisolone until day 5, 0.25 mg/kg/day from day 5 to day 30, and 0.15 mg/kg/day from day 30 to day 90. Afterwards, steroids were withdrawn
Outcomes	Outcomes reported: mortality at maximal follow‐up, graft rejection (any) Follow‐up (months): 6
Notes	Source of funding (quote): "they received funding from the drug companies involved to carry out their research" Trial name/trial registry number: not stated Attempts were made to contact the authors in August 2019.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available
Allocation concealment (selection bias)	Low risk	Quote: "eligible patients were randomized at the beginning of surgery, using sealed envelopes"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "an open‐label, not‐blinded"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "an open‐label, not‐blinded"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: there were post‐randomisation dropouts. It was not clear whether these could be related to the interventions
Selective reporting (reporting bias)	Low risk	Comment: no pre‐published protocol was available, but the authors reported on mortality, graft loss, and adverse events
Other bias	Low risk	Comment: no other bias noted